RxSight (RXST) Competitors

RxSight (NASDAQ:RXST) and Inari Medical (NASDAQ:NARI) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, community ranking, risk, earnings and dividends.

Which has more risk & volatility, RXST or NARI?

RxSight has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Inari Medical has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.

Is RXST or NARI more profitable?

Inari Medical has a net margin of -13.68% compared to RxSight's net margin of -23.92%. Inari Medical's return on equity of -10.09% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-23.92%	-14.00%	-12.51%
Inari Medical	-13.68%	-10.09%	-6.60%

Does the MarketBeat Community prefer RXST or NARI?

Inari Medical received 19 more outperform votes than RxSight when rated by MarketBeat users. However, 68.12% of users gave RxSight an outperform vote while only 57.89% of users gave Inari Medical an outperform vote.

Company	Underperform	Outperform
RxSight	Outperform Votes 47 68.12%	Underperform Votes 22 31.88%
Inari Medical	Outperform Votes 66 57.89%	Underperform Votes 48 42.11%

Do insiders & institutionals have more ownership in RXST or NARI?

78.8% of RxSight shares are owned by institutional investors. Comparatively, 91.0% of Inari Medical shares are owned by institutional investors. 9.4% of RxSight shares are owned by insiders. Comparatively, 10.6% of Inari Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Do analysts prefer RXST or NARI?

RxSight presently has a consensus price target of $58.13, suggesting a potential upside of 91.26%. Inari Medical has a consensus price target of $68.00, suggesting a potential downside of 14.52%. Given RxSight's stronger consensus rating and higher possible upside, research analysts clearly believe RxSight is more favorable than Inari Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Inari Medical	0 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Which has higher valuation & earnings, RXST or NARI?

Inari Medical has higher revenue and earnings than RxSight. Inari Medical is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$89.08M	13.75	-$48.61M	-$0.83	-36.61
Inari Medical	$493.63M	9.43	-$1.64M	-$1.35	-58.93

Does the media prefer RXST or NARI?

In the previous week, RxSight had 9 more articles in the media than Inari Medical. MarketBeat recorded 12 mentions for RxSight and 3 mentions for Inari Medical. RxSight's average media sentiment score of 0.49 beat Inari Medical's score of 0.06 indicating that RxSight is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inari Medical	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

RxSight beats Inari Medical on 10 of the 18 factors compared between the two stocks.